Daily Stock List
ScripsAmerica, Inc. (SCRC)
SmallCapInvestorDaily, OTCtipReporter, PennyStockScholar, and Stock Guru reported on ScripsAmerica, Inc. (SCRC), and we are highlighting the Company as "One to Watch" here at the QualityStocks Daily Newsletter.
ScripsAmerica, Inc. delivers pharmaceutical products to a broad spectrum of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corp. End users include physicians' offices, retail pharmacies, long-term care sites, hospitals, and government and home care agencies. ScripsAmerica provides a strong low cost system of broad base U.S. national marketing, sales, and distribution of generic Rx, branded Rx, OTC, nutraceuticals, and oral delivery OTC pharmaceuticals.
Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, as well as hormonal replacement drugs. ScripsAmerica's other customers include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration.
For consumers, the Company's mission is to provide them the same high quality pharmaceutical, vitamin, and nutritional supplements that they supply nationally to Hospitals & Nursing Homes. Concerning Pharmaceutical Contract Services, ScripsAmerica's service offering includes fulfilling prescription and OTC orders, labeling, packaging, and shipping.
In November 2012, ScripsAmerica announced that Marlex Pharmaceuticals renewed their pharmaceutical supply contract with national nursing home chain, GeriMed. The new agreement extends through September 2014. It can potentially generate $2 million in revenue for Marlex Pharmaceuticals, which ScripsAmerica plans to operate as a wholly owned subsidiary upon their acquisition being finalized.
In December, ScripsAmerica announced that their Chief Executive Officer, Bob Schneiderman, issued a very positive outlook for 2013. Mr. Schneiderman cited how the Company expects to finalize the pending acquisition of Marlex Pharmaceuticals and launch their RapiMed children's pain reliever during the first quarter. Management's goal is to implement a regional launch of the RapiMed product line shortly after the beginning of 2013. ScripsAmerica expects that the acquisition of their current packager, Marlex Pharmaceuticals, will immediately increase the Company's profits by 10 to 15 percent.
We have ScripsAmerica, Inc. (SCRC) in our sightlines as "One to Watch" this week here at the QualityStocks Daily Newsletter.
ScripsAmerica, Inc. (SCRC), closed Wednesday's trading session at $0.29, down 1.69%, on 10,000 volume with 1 trade. The average volume for the last 60 days is 14,455 and the stock's 52-week low/high is $0.22/$0.51.
Soul and Vibe Interactive, Inc. (SOUL)
Today we are highlighting Soul and Vibe Interactive, Inc. (SOUL) as "One to Watch" here at the QualityStocks Daily Newsletter.
Trading on the OTC Bulletin Board, Soul and Vibe Interactive, Inc. operates as a video and computer games company. The Company focuses on developing and publishing prominent games. Soul and Vibe Interactive publishes games and games-related content for consoles, mobile devices, and personal computers. The Company formerly went by the name Victory LG, Inc. They changed their corporate name to Soul and Vibe Interactive, Inc. in October of 2012. The Company has their headquarters in St. Louis Park, Minnesota.
Soul and Vibe Interactive's product family encompasses a mix of licensed-brands and internally generated, wholly owned intellectual properties. The Company has development partnerships with a variety of software development companies that have experience in developing "pick-up-and-play" sports, active-lifestyle, platform, racing, as well as action games.
Soul and Vibe Interactive specializes in the creation of original intellectual properties (IPs). Their business model focuses on multi-platform support. The Company's licensed-brand and original IP-based games can be played on consoles, mobile devices, and personal computers (PCs). A recurring release of monetized games-related content supports each product.
Ancillary revenue is from the sale of Premium Downloadable Content (PDLC), virtual apparel and costumes for Avatars, and monetized "Consumables." The Company's business model calls for several revenue streams to be generated from each game release. Their mobile games are revenue generating marketing vehicles for their console releases.
By way of "Smart Glass" and "Companion App" support, the Company broadens consumer awareness for each game franchise, promotes interconnectivity between hardware platforms for their games, and amortizes development and marketing expenses. "IP" ownership allows Soul and Vibe Interactive to control the licensing of their properties to Third Party merchandising companies and to retain the majority of revenues.
Mr. Peter Anthony Chiodo (Tony) is the Vice President and a Member of the Board of Directors of Soul and Vibe Interactive. Mr. Chiodo has 22 years experience in the video and computer games industry as an award-winning Director of Product Development and Producer. He has launched 200-plus video and computer games over the course of his career. He has broad experience leading software production teams, globally, in the development of engine technologies and games for consoles and personal computers.
We're keeping an eye on Soul and Vibe Interactive, Inc. (SOUL) and tracking them on our radar screens as "One to Watch" here at the QualityStocks Daily Newsletter.
Soul and Vibe Interactive, Inc. (SOUL), closed Wednesday's trading session at $0.311, even for the day. The average volume for the last 60 days is 7,347 and the stock's 52-week low/high is $0.29/$1.45.
Gold Crest Mines, Inc. (GCMN)
Wall Street Corner reported previously on Gold Crest Mines, Inc. (GCMN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Gold Crest Mines, Inc. is in the business of exploration, development, and if warranted the mining of properties containing valuable mineral deposits. The Company explores for precious metals, primarily gold. Founded in 2005, Gold Crest Mines lists on the OTC Bulletin Board. The Company has their corporate headquarters in Spokane, Washington.
Gold Crest Mines holds interests in exploration properties covering acreage located in southwest Alaska. In the Kisaralik Lake area of southwest Alaska, the Company's wholly owned subsidiary Kisa Gold Mining, Inc. (KGMI) controls or has interests in claim blocks consisting of 274 State of Alaska mining claims covering approximately 42,420 acres. Gold Crest Mines calls the claim blocks the Southwest Kuskokwim Project and the Buckstock Project. The individual names of each claim block are Kisa, Gold Lake, Luna, AKO, Chilly, Gold Creek, Gossan Valley, as well as Little Swift.
On March 28, 2011, Gold Crest Mines, by way of their wholly owned subsidiary, Kisa Gold Mining, executed a Master Earn-In agreement with North Fork LLC, an Alaska Limited Liability Company (LLC). This agreement calls for North Fork to explore for gold deposits on Kisa's claim blocks in the Southwest Kuskokwim Project area and Buckstock Project area (Projects). The Projects consist of Gold Crest Mines aforementioned exploration properties.
The Company continues to proceed with their Joint Venture (JV) partner, North Fork. This JV partner continues to expend funds under the Master Earn-In agreement; they are working on another season of exploration in Gold Crest Mines' Southwest Kuskokwim Project area.
On July 26, 2012, Gold Crest signed a Loan Facility Agreement for $15,000 with Afranex Gold Ltd. Afranex is a company related to Gold Crest's JV partners North Fork Resources Pty Ltd. The agreement entitled Gold Crest to make individual drawdowns in $5,000 increments of the Loan until the Loan has been exhausted to provide the Company with immediate working capital requirements. During the quarter ending September 30, 2012, they received the entire amount of the loan. On October 26, 2012, they signed the First Deed of Variation to the Loan dated July 26, 2012; the loan amount was increased from the original amount of $15,000 to $25,000. This entitles Gold Crest to make individual drawdowns in $5,000 increments of the increased Loan until the Loan has been exhausted to provide the Company with immediate working capital requirements.
On October 31, 2012, they received the first additional requested draw of $5,000. The Company agrees to repay the loan in full on or before January 31, 2013 and/or agrees that the funds will be deducted from the $100,000 cash payment that forms part of the agreed consideration to purchase the Company's wholly owned subsidiary, Kisa Gold Mining.
Gold Crest Mines, Inc. (GCMN), closed Wednesday's trading session at $0.02, up 17.65%, on 38,554 volume with 2 trades. The average volume for the last 60 days is 38,554 and the stock's 52-week low/high is $0.005/$0.045.
L & L Energy, Inc. (LLEN)
Wall Street Resources reported yesterday on L & L Energy, Inc. (LLEN), SmarTrend Newsletters, CRWEWallStreet, CRWEFinance, StockHotTips, CRWEPicks, PennyToBuck, DrStockPick, PennyOmega, RedChip, StreetInsider did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Seattle, Washington, L & L Energy, Inc. is a coal-mining company that lists on the NASDAQ Global Select market. The Company is a member of the American Coal Council, one of the country's largest coal trade associations representing the business interest of the American coal industry. Founded in 1995, L & L Energy, through the Company's subsidiaries, engages in the coal mining, clean coal washing, coal coking, and coal wholesale businesses in the People's Republic of China (PRC). L & L Energy focuses on high margin coal operations.
The Company operates profitable coalmines, coal wholesale, and coal- washing facilities in Yunnan and Guizhou Provinces. L & L Energy offers thermal or steam coal to state owned enterprises. They are also engaged in producing, processing, and selling metallurgical coal primarily used in the steel manufacturing process, as well as coking coal.
L & L Energy provides their products to customers in the steel and the electrical/utility industries, as well as to cement factories. The Company sells their products directly and through third-party wholesalers.
Last month, L & L Energy announced their financial results for their second quarter of fiscal 2013. Coal mining production increased 93 percent year over year to 185,000 tons in the second quarter of fiscal 2013 from 96,000 in the same quarter a year ago. Quarter over quarter production increased 24 percent from 149,000 tons in the first quarter.
Revenues increased 27 percent year-over-year to $54.9 million in the second quarter of fiscal 2013. On a quarter over quarter basis, revenues increased 21 percent from $45.3 million last quarter. Net income attributable to L&L increased 104 percent year-over-year to $7.7 million for the second quarter of fiscal 2013 and increased quarter over quarter 24 percent from $6.2 million last quarter. Earnings per share for the quarter were $0.21. This represents an increase of 90 percent when compared to the same period a year ago and an increase of 24 percent quarter over quarter.
L & L Energy, Inc. (LLEN), closed Wednesday's trading session at $1.90, up 1.06%, on 50,445 volume with 92 trades. The average volume for the last 60 days is 170,285 and the stock's 52-week low/high is $1.30/$3.25.
RepliCel Life Sciences, Inc. (REPCF)
Greenbackers, The Green Baron, Stock Guru, Investor Spec Sheet, The Stock Advisor, and Club Penny Stocks Network reported earlier on RepliCel Life Sciences, Inc. (REPCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
RepliCel Life Sciences, Inc. is developing an autologous cell-based procedure for the treatment of androgenetic alopecia (pattern baldness) and general hair loss in men and women. The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world's first minimally invasive solution for pattern baldness. RepliCel Life Sciences has their headquarters in Vancouver, British Columbia.
RepliCel established to advance the innovative findings of Dr. Kevin McElwee and Dr. Rolf Hoffmann, established research scientists in the fields of immunology, hair biology, hair growth, and dermatology. In the early 2000s, at Phillips University in Marburg, Germany, Drs. McElwee and Hoffmann discovered that dermal sheath cup cells have the ability to initiate cellular growth of mature hair follicles in animals. The Company is presently developing this discovery as a potential treatment for hair loss in humans.
The design of their patented hair follicle cell replication and implantation technology is to initiate natural hair regeneration and to rejuvenate existing dormant hair follicles in patients suffering from pattern baldness. Their treatment is especially promising for women who generally shy away from highly invasive micro transplant surgery and drug treatments that may cause side effects. Patents for the technology have been issued by the European Union and Australia. Patents are pending in other major international jurisdictions. In addition to the discovery of the critical cell population believed to be responsible for hair follicle growth, RepliCel has created a proprietary method for extracting and replicating these cells.
In November 2012, RepliCel Life Sciences reported on their pre-filing scientific meeting with the German Competent Authority responsible for cellular therapies - the Paul Ehrlich Institute (PEI). During the latter part of 2012, the Company made enhancements to the RepliCel™ procedure to improve the quality, characterization, and shelf life of their autologous hair cell product - named RCH-01.
The Company's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on their proposed current Good Manufacturing Practice (cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of the Company's upcoming Phase II, dose-ranging clinical trial. The expectation is that the Phase II Dose Ranging Trial on their hair cell replication technology will begin in mid-2013.
RepliCel Life Sciences, Inc. (REPCF), closed Wednesday's trading session at $0.48, up 9.09%, on 6,387 volume with 4 trades. The average volume for the last 60 days is 5,308 and the stock's 52-week low/high is $0.30/$2.74.
China Liaoning Dingxu Ecological Agriculture Development, Inc. (CLAD)
We are highlighting China Liaoning Dingxu Ecological Agriculture Development, Inc. (CLAD), here at the QualityStocks Daily Newsletter.
China Liaoning Dingxu Ecological Agriculture Development, Inc. engages in growing and marketing mushroom and related agricultural products. These include mushroom spawn and mushroom seeds through their affiliated variable interest entity LiaoNing DingXu. Founded in 2009, the Company has their corporate headquarters in Dalian, the People's Republic of China (PRC). China Liaoning lists on the OTC Bulletin Board.
The Company primarily produces and sells two types of products. One is Fresh Mushrooms. They grow fresh mushrooms in their greenhouse and sell them to markets. China Liaoning's fresh mushrooms include oyster mushrooms, king oyster mushrooms, king trumpet mushrooms, and button mushrooms. The revenues from the sales of fresh mushrooms constitute approximately 55 percent and 70 percent of the Company's total revenues in the half year of 2012 and 2011, respectively.
The other type of product that China Liaoning sells is related mushroom products. These include the aforementioned mushroom spawn and mushroom seeds. The revenues from the sales of related mushroom products constitute approximately 45 percent and 30 percent of the Company's total revenues in the half year of 2012 and 2011, respectively.
Over the long term, China Liaoning expects to see a trend of growing sales for their mushroom series products. The Company believes this will result from the growing of market scales, the improvement of the general agricultural industry, the improvement of planting skills and the quality of their products. In addition, the Company believes they will experience growing sales because of the continuing encouragement from local government.
China Liaoning believes that as they continue to invest to develop their mushroom planting greenhouse and structures, and mushroom seeds cultivation workshop and manufacturing workshop, the categories and total quantities of their products would be much higher than they produced in the last period. During the nine months ended September 30, 2012, the Company's operating activities provided $1,150,735 in net cash.
China Liaoning Dingxu Ecological Agriculture Development, Inc. (CLAD), closed Wednesday's trading session at $0.07, even for the day. The average volume for the last 60 days is 2,912 and the stock's 52-week low/high is $0.035/$0.79.
Vitamin Blue, Inc. (VTMB)
Pennystocktweeters.com, Center Stage Stocks, AlphaPennyStock, Apex Pennystocks, Otcstockexchange, marketwirepress, and Whisper from Wall Street reported this week on Vitamin Blue, Inc. (VTMB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 1999, Vitamin Blue, Inc. designs, develops, produces and distributes water boardsports apparel, accessories and related products. The Company is part of the consumer goods sector and non-durables industry. Their founder, Mr. Frank D. Ornelas, still personally oversees all aspects of the business at the Company's facilities. Vitamin Blue has their corporate headquarters in Costa Mesa, California. Their shares trade on the OTC Bulletin Board.
At their online store, Vitamin Blue offers products in three categories. These are Boardshorts and Tee Shirts, Boardbags, and Accessories. Vitamin Blue makes and sells surf wear under the Vitamin Blue name. Moreover, the Company private labels water sports accessories (surfboard bags, SUP bags, paddle bags and roof rack pads) and custom board bags of all kinds.
Their products are designed in their Costa Mesa facility. The Company's products are available online as well as at surf shops, at surfboard shapers, at stand up paddleboard (SUP) shops and SUP shapers. Vitamin Blue also manufactures water boardsports accessories for BARK BOARDS, Inc., Hobie, Icons of Surf, Infinity Surfboards, King's Paddle Sports, QuickBlade, Inc. and others.
On Monday, Vitamin Blue announced that their year over year sales increased by over 25 percent. This was in line with their goals of growing sales while minimizing cost of sales. The estimation is that the global surfing industry will reach $13.2 billion by 2017, according to a new report by Global Industry Analysts, Inc.
Today, Vitamin Blue announced that they launched a redesign of their website at www.vitaminblue.com. The new website design provides the ability to search for products, review items in detail with high-quality images, and order online. The site soft launched at the beginning of Q4 2012. Compared to Q4 2011, VitaminBlue.com more than doubled year over year in unique visitors (+82 percent) and Page Views (+56 percent) in Q4 2012.
Vitamin Blue, Inc. (VTMB), closed Wednesday's trading session at $0.085, up 6.25%, on 1,287,033 volume with 101 trades. The average volume for the last 60 days is 16,243 and the stock's 52-week low/high is $0.085/$0.75.
Lone Star Gold, Inc. (LSTG)
UltimatePennyStock reported yesterday on Lone Star Gold, Inc. (LSTG), Pumps and Dumps, Wyatt Investment Research, TheStockAdvisor, Investor Spec Sheet, Weiss Research, Another Winning Trade did earlier, and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCBB, Lone Star Gold, Inc. is a gold exploration and development company. Their acquisition and exploration approach strategically focuses on proven, stable precious metal regions in America and Mexico. Lone Star Gold has their headquarters in Albuquerque, New Mexico.
Currently, Lone Star Gold has a 70 percent Working Interest (WI) in concessions covering 800 hectares in the La Candelaria project in Chihuahua, Mexico. The Company is evaluating these to determine the potential sites that represent the best potential for silver and gold deposits. Property access is through established roadways from the capital city of Chihuahua. Nearby infrastructure includes an airstrip and telecommunication services at the town of Tonachi.
Furthermore, the Company has an undivided 65 percent interest in the San Antonio del Potrero mine tailings project near the city of Hidalgo Del Parral in the state of Chihuahua, Mexico. Lone Star's due diligence exploration of the San Antonio del Potrero mine tailings project included 10 holes augured to acquire 40 undisturbed samples at depths of 20-25 meters, which yielded positive drilling results. The estimated mine life is 8.3 years at 600 tpd and 6.2 years at 800 tpd.
In July 2012, Lone Star Gold provided an update on their Tailings Project operations and expansion near the city of Hidalgo Del Parral. The Company's team in Mexico completed all preliminary study regarding the construction of a benign nitrogen leaching pile process plant on the Tailings Property. The leaching plant will be capable of processing greater than 1,000 tpd. This relatively new leaching process represents the benefits of not using cyanide and of having minimal environmental impact. The Mexico team put together a team of metallurgists, engineers and construction crews to execute the leaching plant construction once all the necessary permits are in place.
On Monday of this week, Lone Star Gold announced the effectiveness of their Form S-1 dated December 20, 2012, which outlines the details of their $15 million Common-Stock-Purchase Investment Agreement with Deer Valley Management, LLC. Lone Star's intention is to raise capital through the Deer Valley Investment Agreement beginning this month. Lone Star will begin construction as soon as possible on their own on-site processing plant at their Tailings Project near the city of Hidalgo Del Parral. They expect the on-site processing plant to be operational within 3-4 months following access to the necessary funding through the Deer Valley Investment Agreement.
Lone Star Gold, Inc. (LSTG), closed Wednesday's trading session at $0.158, up 73.63%, on 2,466,939 volume with 313 trades. The average volume for the last 60 days is 177,246 and the stock's 52-week low/high is $0.03/$0.70.
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.06, even for the day. The stock’s average daily volume over the past 60 days is 8,410, and its 52-week low/high is $0.01/$0.39.
Loans4Less.com, Inc. made ready certain preliminary financial results today for the fiscal year (ended Dec 31, 2012), showing a 61% jump in revenues over 2011 figures, with annual net ordinary income also up 41% on strong headwind from the writing down of some $98k in revolving debt from free cash flow. Chairman and President of the company, Steven M. Hershman, noted mortgage rates being near record lows and how this is leading to considerable traction in purchase activity, with prevailing market conditions acting as a catalyst for this online mortgage loan brokerage firm who is quickly becoming a national loan origination platform for standard "A" paper conforming residential mortgage programs.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com, Inc. Provides Preliminary Financial Results for Year Ended December, 31 2012
Loans4Less.com, Inc. Reports Financial Results for the Third Quarter of 2012
Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.10, up 25.00%, on 25,100 volume with 6 trades. The stock’s average daily volume over the past 60 days is 57,902, and its 52-week low/high is $0.0069/$0.10.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount’s Freedom Security Software Installed at Additional U.S. Government Facilities
SoundView Technology Group Issues Research Report on Viscount Systems
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.03, up 20.00%, on 295,954 volume with 15 trades. The stock’s average daily volume over the past 60 days is 230,742, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Achieves Current Information Status on OTC Markets
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
Bergamo Acquisition Updates Financials
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.049, up 5.38%, on 12,323,628 volume with 361 trades. The stock’s average daily volume over the past 60 days is 2,183,631, and its 52-week low/high is $0.0275/$0.179.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Present at the 6th Annual OneMedForum
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
Earlier this morning, Loans4Less.com provided certain preliminary financial results for the year ended December 31, 2012. Revenues for the year are expected to increase by approximately 61% compared to the prior year. Annual Net Ordinary Income is 41% greater compared to 2011. An improvement of $58K in the balance sheet is also anticipated with $98K in revolving debt paid off from free cash flow.
According to today’s press release, the complete 2012 annual report and financial results will be posted in due course. E&OE.
Loans4Less.com projects the mortgage origination market will stay very active this year even though lender underwriting standards are allowing only best credit quality borrowers to close on their loans. The current mortgage market mainly consists of Fannie Mae/Freddie Mac Conforming fixed rate loans for refinancings.
“Purchase activity is gaining traction with mortgage rates near record lows,” Steven M. Hershman, Chairman & President, commented. “Loans4Less.com sees highly favorable market conditions as a catalyst for ongoing significant improvement in our business growth and future expansion.”
For more information, visit www.loans4less.com
The 1966 science fiction movie Fantastic Voyage tells the futuristic story of an attempt to save a man’s life by using a new miniaturization technology. In the movie, a specially designed submarine and crew are reduced in size to a microscopic dot, allowing scientists to inject them into the patient where they are able to destroy a blood clot and save the patient’s life. An incredible story, but one with parallels to the research and development being carried out by New Jersey based biotechnology company Advaxis.
Advaxis is developing ways to use tiny bio-engineered bacteria to manipulate the human immune system as a unique way of fighting cancer and infectious diseases, like training millions of micro-surgeons to operate deep inside the body. The company’s immunotherapy platform technology is based on the use live, attenuated bacteria, bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to attack the cancer itself.
Over 15 distinct constructs are in various stages of development, either developed directly by Advaxis or through collaboration with recognized centers of excellence around the country and the world. Advaxis’ first construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, head and neck cancer). In 2012, Advaxis won an award for the Best Therapeutic Vaccine at the 5th Annual Vaccine Industry Excellence Awards in Washington, DC.
This week, Advaxis Chairman and CEO, Tom Moore, presented at the 6th Annual OneMedForum, a gathering of leading investors and management for some of the most promising emerging life science companies in Asia and North America, where he spoke about developing the next generation of cancer immunotherapies. It was an important opportunity to make the company’s case to investors, and it didn’t hurt that ADXS shares have recently jumped over 80% after getting coverage from the GotStockTips SMS alert service.
For additional information, visit www.Advaxis.com
A recent Reuters report indicates that West Antarctica is warming at a rate nearly twice as fast as previously thought, almost 3 times the global average. The warming is of special concern since West Antarctica has enormous ice sheet glaciers, which an ice shelf collapse could release, speeding their flow to the ocean and contributing to significant sea level rise. If West Antarctica were to melt entirely, sea level could rise by 11 feet. It comes on top of news that 2012 could end up being the hottest year in U.S. history, a year where the month of July set the record as being the hottest single month in the U.S. since weather records began back in 1895.
It’s a seemingly endless flow of news about global warming that continues to drive efforts to reduce greenhouse gas emissions. Industrialized nations have been reducing greenhouse gas emissions, and now China is setting caps on coal use, while other developing countries increasingly look toward alternative energy sources.
For VIASPACE, provider of proprietary Giant King Grass (GKG), a dedicated biomass crop offering exceptionally high yields, the growing global crisis represents almost unlimited opportunities. GKG easily fits into the existing combustion oriented power industry infrastructure but represents zero-carbon energy production. When the crop grows, it absorbs carbon, balancing out the carbon released during burning in power plants. It’s more economical than solar or wind, and does not rely on weather or sun conditions for power production. In short, GKG is the ideal answer for an energy hungry world that needs to drastically limit greenhouse gas emissions, and the company has been actively signing contracts around the world to supply GKG. VIASPACE is also working with partners to develop other green bioenergy projects that can use Giant King Grass. For example, GKG can be used as a feedstock to make liquid transportation biofuels, such as green gasoline.
For more information on VIASPACE and its energy crop, visit www.VIASPACE.com
On December 20th, 2012, PositiveID Corporation (PSID) announced they have teamed up with The Boeing Company for a licensing agreement that could lead to big profits for both companies. The Boeing Company will manufacture and sell PositiveID’s M-BAND bio-threat detection devices in North America, while PositiveID secures reoccurring revenue streams by retaining the rights to sell the reagents and assays for the devices.
What is Bio Watch 3?
Bio Watch Generation 3, a program being procured by Homeland security and estimated to cost $3 billion, involves the deployment and testing of an estimated 2,500 M-BAND units as part of the Department of Homeland Security’s Bio Watch Generation 3 program, set to roll out over the next five to six years.
The Power of M-BAND
Appropriately called a “lab in a box”, PositiveID Corporation’s M-BAND bio-threat detection devices take up about as much space as a modern industrial fridge. Developed under contract for the Department of Homeland Security Science and Technology Division, M-BAND is a bio aerosol monitor designed to perform sample collection, data processing and detection, continuously analyzing air samples for a range of certain airborne pathogens such as bacteria, viruses and toxins. Since resulting data from individual M-BAND machines gets communicated in real time via a secure wireless network, this system promises to provide accurate and current information to connected field instruments. When operated as an integrated system, an M-BAND network becomes a solid warning system and the foundation of the Bio Watch 3 program.
The current system for analyzing and detecting potential bio-threats requires at least 36 hours and sometimes more before a threat can be identified. The M-BAND system can go from detection to alert in 4 to 6 hours, dramatically faster.
The Agreement Explained
The licensing agreements and teaming agreements between these two companies specifies that The Boeing Company will have the exclusive right to manufacture, market and sell the M-BAND threat detection devices in North America to the United States government specifically for use in the Bio Watch 3 program. PositiveID Corporation will retain the rights to be the exclusive provider of all reagents and assays for all M-BAND units sold by Boeing, as well as international rights.
The Boeing Company is the world’s largest and most versatile manufacturer of military aircraft, and their unit called Boeing Defense, Space & Security claims a title of equal importance as the world’s largest defense, space and security businesses. A partnership with a company as large and successful as Boeing can only spell success for an emerging medical technology company like PositiveID Corporation.
How will License agreement affect PositiveID?
Chairman and CEO of PositiveID, William J. Caragol explained the true importance of PositiveID Corporation’s agreement with Fortune 50 company Boeing in a recent interview. “Think of it as the razor blade, with the M-BAND being the razor, model.” He says that the reagent and assay business is important to them because by retaining the right to provide reagents and assays, which will be needed on a monthly basis, PositiveID has strategically secured a solid reoccurring revenue stream in a market estimated to generate 90-120 million in annual revenue with 10-15% margins.
Based on the schedule released by the Department of Homeland Security, the first stage of Bio Watch Generation 3 includes initial pilots and testing of M-BAND units and is scheduled to be procured by 2013.
In addition to retaining the right to sell reagents and assays, PositiveID also still retains the right to sell the M-BAND systems, reagents and assays internationally. When recently asked about the realistic potential for an international market, Caragol reported that PositiveID has “actually taken some inbound inquiries … both from Europe, as well as from the Middle East, allies of the US inquiring about the ability to use the systems and implement the systems … for the very same homeland protection that the US is looking to do.” He claims that as the Bio Watch 3 program gains recognition as a successful project, international buyers will begin showing strong interest in implementing these same systems in their areas.
PositiveID Pursues Opportunities with SAIC
CEO Caragol claims that PositiveID’s agreements with Boeing leave PositiveID free to pursue other opportunities in the defense arena as well, such as defense threat reduction agency contracts. In November 2011, PositiveID announced a teaming agreement with Science Applications International Corporation (SAIC) to pursue opportunities with the Defense Treat Reduction Agency (DTRA). With these recent contracts and teaming agreements, PositiveID Corporation seems to have paved the way for outstanding success in 2013.
In addition to bio-threat detection technology, PositiveID’s HealthID division is focused on providing health solutions for consumers, businesses and animals, such as blood glucose monitoring, rapid virus detection, and various other products aiding diabetes management. Products announced so far include iglucose, Easy Check and GlucoChip.
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Present at the 6th Annual OneMedForum
- Bergamo Acquisition Corp. (BGMO) Achieves Current Information Status on OTC Markets
- Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report With the Securities and Exchange Commission
- Cardium Therapeutics, Inc. (CXM) To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
- The Guitammer Company Inc. (GTMM) Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
- GlobalWise Investments, Inc. (GWIV) Enters New Channel Sales Partnership With Iron Data
- International Stem Cell Corp. (ISCO) Announces Positive Animal Efficacy Results in Liver Disease Program
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for Year Ended December, 31 2012
- TNI BioTech Inc. (TNIB) Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel
- Viaspace, Inc. (VSPC) CEO Invited to Speak At EUEC2013 Conference and Company to Feature GiantKing™ Grass in Exhibit Hall
- Viscount Systems, Inc. (VSYS) Freedom Security Software Installed at Additional U.S. Government Facilities
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium